focus -WSS

focus

author：leisure time 2025-10-02 03:11:18 Page View：47

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars
Next article： Activists slam private health insurers over coverage restrictions

comprehensive

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

The Readout: Amylyx, Alumis, and Lundbeck drug updates

AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

Continuity nursing helped my family in our darkest PICU moments

EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3

Air quality improving but still lags in Black, Hispanic communities

High-risebuildingsindowntownLosAngelesseenonahazymorning.FREDERICJ.BROWN/AFPviaGettyImagesTheU.S.ism